Secondary polycythemia in chronic obstructive pulmonary disease: prevalence and risk factors

Jingzhou Zhang1,2, Dawn L. DeMeo2,3, Edwin K. Silverman2,3, Barry J. Make4, R. Chad Wade5, J. Michael Wells5,6, Michael H. Cho2,3† and Brian D. Hobbs2,3*†

Abstract
Background: Secondary polycythemia is associated with cigarette smoking and chronic obstructive pulmonary disease (COPD). However, the prevalence of polycythemia in COPD and the contributing risk factors for polycythemia in COPD have not been extensively studied.

Methods: We analyzed the presence of secondary polycythemia in current and former smokers with moderate to very severe COPD at the five-year follow-up visit in the observational COPDGene study. We used logistic regression to evaluate the association of polycythemia with age, sex, race, altitude, current smoking status, spirometry, diffusing capacity for carbon monoxide (DLCO), quantitative chest CT measurements (including emphysema, airway wall thickness, and pulmonary artery to aorta diameter ratio), resting hypoxemia, exercise-induced hypoxemia, and long-term oxygen therapy.

Results: In a total of 1928 COPDGene participants with moderate to very severe COPD, secondary polycythemia was found in 97 (9.2%) male and 31 (3.5%) female participants. In a multivariable logistic model, severe resting hypoxemia (OR 3.50, 95% CI 1.41–8.66), impaired DLCO (OR 1.28 for each 10-percent decrease in DLCO % predicted, CI 1.09–1.49), male sex (OR 3.60, CI 2.20–5.90), non-Hispanic white race (OR 3.33, CI 1.71–6.50), current smoking (OR 2.55, CI 1.49–4.38), and enrollment in the Denver clinical center (OR 4.42, CI 2.38–8.21) were associated with higher risk for polycythemia. In addition, continuous (OR 0.13, CI 0.05–0.35) and nocturnal (OR 0.46, CI 0.21–0.97) supplemental oxygen were associated with lower risk for polycythemia. Results were similar after excluding participants with anemia and participants enrolled at the Denver clinical center.

Conclusions: In a large cohort of individuals with moderate to very severe COPD, male sex, current smoking, enrollment at the Denver clinical center, impaired DLCO, and severe hypoxemia were associated with increased risk for secondary polycythemia. Continuous or nocturnal supplemental oxygen use were associated with decreased risk for polycythemia.

Keywords: COPD, DLCO, Hypoxemia, Oxygen therapy, Polycythemia

Background
Cigarette smoking and chronic obstructive pulmonary disease (COPD) are associated with secondary polycythemia [1, 2], which may contribute to pulmonary hypertension (PH) [3, 4], venous thromboembolism [5–7], and mortality in COPD [8–11].
Polycythemia prevalence in COPD outpatients ranges from 6 to 10.2% when defined by a hemoglobin ≥17 g/dL in males and ≥15 g/dL in females [9, 12, 13]. The prevalence of a hematocrit ≥55% was 8.4% in a sample of patients with severe COPD receiving long-term oxygen therapy (LTOT) [11]. Polycythemia in COPD has been noted to be less frequent following the widespread use of LTOT [14], yet a secular trend in polycythemia prevalence has not been well-established due to a lack of comparable samples of COPD patients across the full spectrum of disease severity. Additionally, in 2016 the World Health Organization (WHO) redefined polycythemia vera (a myeloproliferative neoplasm) as a hemoglobin >16.5 g/dL and/or a hematocrit >49% in males and a hemoglobin >16.0 g/dL and/or a hematocrit >48% in females [15]. The diagnosis of secondary polycythemia is extrapolated from the WHO definition for polycythemia vera. The prevalence of secondary polycythemia is unclear in a contemporary COPD population due to the recent change in the definition of polycythemia and an increased use of LTOT in COPD patients.

Increased carboxyhemoglobin (COHb) in active smokers and chronic hypoxemia in COPD patients are proposed to contribute to the development of secondary polycythemia; however, the underlying physiological mechanisms are not fully understood [1, 14, 16]. Hematocrit has been negatively correlated with: age, forced expiratory volume in 1 s (FEV₁) percent predicted, and ratio of FEV₁ to forced vital capacity (FVC); and positively correlated with: male sex, current smoking, partial pressure of carbon dioxide in the blood, and body mass index (BMI) in COPD patients [11]. However, secondary polycythemia risk factors have not been examined in an extensively phenotyped sample of COPD patients with and without hypoxemia. This study aims to evaluate the prevalence and risk factors of secondary polycythemia in a cohort of current- and former-smoking COPD patients in the Genetic Epidemiology of COPD (COPDGene) study. Part of the results of this study were published as an abstract for the 2020 American Thoracic Society annual meeting.

Methods
Study design and population
We performed a cross-sectional analysis of selected participants from the COPDGene study (ClinicalTrials.gov Identifier: NCT00608764), an ongoing prospective observational study involving twenty-one clinical centers across the United States. Study design and methodology for COPDGene have been previously reported and are available online at www.COPDGene.org [17]. Briefly, the COPDGene study included participants aged 45 to 80 years with self-identified race/ethnicity of non-Hispanic white or African American and at least a 10 pack-year smoking history. Participants of the COPDGene study were asked to complete a demographic questionnaire and report their self-identified race as White, Black or African American, Asian, Pacific Islander, American Indian, and Other. The participants were also asked to report their self-identified ethnicity as Hispanic or Latino vs. Not Hispanic or Latino. Only participants identifying as “White” or “Black/African American” and “Not Hispanic or Latino” were eligible to participate given the study design of COPDGene study. Ancestry was assessed using genetic data and was confirmed to match well with self-identified race [18]. Current smoking status and pack-years of cigarette smoking were obtained based on self-report. COPD-related phenotypes including clinical, physiological, laboratory, and imaging features were collected in COPDGene. Our polycythemia investigation included participants from the COPDGene 5-year-follow-up visit with Global Initiative for Chronic Obstructive Lung Disease (GOLD) grade 2–4 airflow limitation severity (post-bronchodilator FEV₁/FVC <0.7 and FEV₁% predicted <80%) and available complete blood count (CBC) data. All phenotypic data were from the COPDGene 5-year follow-up visit with the exception of main pulmonary artery to ascending aorta diameter ratio (PA/A) which was obtained at the baseline COPDGene visit. The COPDGene study was approved by the respective Institutional Review Boards at all participating clinical centers, which are outlined in the Additional file 2. Written informed consent was obtained from each study participant.

Polycythemia
The assignment of a secondary polycythemia diagnosis was extrapolated from the 2016 WHO diagnostic criteria for the myeloproliferative neoplasm, polycythemia vera (PV): hemoglobin >16.5 g/dL and/or hematocrit >49% in males; hemoglobin >16.0 g/dL and/or hematocrit >48% in females [15]. The hemoglobin and hematocrit values were obtained from CBC data obtained at the COPDGene 5-year-follow-up visit.

Pulmonary function testing
Spirometry and the diffusing capacity of the lungs for carbon monoxide (DLCO) were measured using the ndd EasyOne system (Zurich, Switzerland) in accordance with the 2005 ATS/ERS guidelines [19]. Spirometry was measured before and after administration of inhaled albuterol, and postbronchodilator spirometry was used in the present study. Extensive quality control of pulmonary function test data was performed by both an automated system and manual review. FEV₁ and FVC percent predicted values were calculated with the National Health
and Nutrition Examination Survey III equations [20]. DLCO was adjusted for hemoglobin and altitude, and DLCO percent predicted values were calculated based on the Global Lung Initiative 2012 reference equations [21, 22].

Chest computed tomography imaging
All participants had inspiratory and expiratory chest CT scans using whole-lung volumetric multidetector CT scanners with a standardized protocol [17]. Quantitative analysis of CT scans was performed using LungQ software (Thirona, Nijmegen, Netherlands, https://thirona.eu). Percent emphysema (% emphysema) and percent air trapping (% air trapping) were defined as percentage of low attenuation lung areas below − 950 Hounsfield units on inspiratory CT and below − 856 Hounsfield units on expiratory CT, respectively [23–26]. Airway wall thickness was quantified as the square root of the wall area of a theoretical airway of 10 mm internal perimeter (Pi10) [27]. Vasculature measurements were performed on axial images of inspiratory CT from the COPDGene baseline study visit using DICOM software (OsiriX DICOM Viewer v4.0, www.osirix-viewer.com). Diameter of the main pulmonary artery was measured at its bifurcation, and diameter of the ascending aorta was measured at the same level in its maximum dimension. Pulmonary artery to aorta (PA/A) ratio was calculated, and relative PA enlargement was defined as a PA/A ratio greater than 1 [28, 29].

Oxyhemoglobin saturation measurement
Oxyhemoglobin saturation (SpO₂) was measured by a pulse oximeter placed on a finger without nail polish. When a strong pulse was demonstrated on oximetry by a pulse oximeter placed on a finger without nail polish. When a strong pulse was demonstrated on oximetry, SpO₂ readings were monitored for at least one minute and a median value was recorded. Resting SpO₂ was measured with participants in a seated position and resting SpO₂ was recorded as 82% if SpO₂ dropped to 82% or lower. Supplemental oxygen was discontinued for at least five minutes prior to testing for participants who used oxygen therapy at rest [30]. For participants who completed a six-minute walk test (6MWT), exercise SpO₂ was measured immediately after completion of the 6MWT. A participant could continue using supplemental oxygen during the 6MWT if the participant routinely used oxygen therapy with exercise.

Long-term oxygen therapy (LTOT)
Participants who reported the use of LTOT on a questionnaire were further asked to provide information on the situations in which they used LTOT (at rest, and/or during sleep, and/or during exercise) as well as the number of hours of supplemental oxygen use on a typical day. LTOT use was classified into four categories: (1) continuously (self-reported supplemental oxygen use both at rest and during sleep, or oxygen use at rest with more than 20 h per day); (2) nocturnally (during sleep only, or during sleep and exercise); (3) intermittently (at rest and/or during exercise without use during sleep); and (4) no use.

COPD comorbidities
Common COPD comorbidities including congestive heart failure, diabetes, chronic kidney disease, and obstructive sleep apnea were self-reported. For participants reporting physician-diagnosed obstructive sleep apnea (OSA), further information on use of the use of a continuous positive airway pressure (CPAP) device was obtained.

Statistical analysis
Resting SpO₂ was categorized as normal (> 95%), mild hypoxemia (93–95%), moderate hypoxemia (89–92%), and severe hypoxemia (≤ 88%). Exercise-induced desaturation (EID) was defined as an SpO₂ drop ≥ 4% from resting SpO₂ and to < 90% at the end of 6MWT [31–33]. LTOT use was classified into four categories: (1) continuously (self-reported supplemental oxygen use both at rest and during sleep, or oxygen use at rest with more than 20 h per day); (2) nocturnally (during sleep only, or during sleep and exercise); (3) intermittently (at rest and/or during exercise without use during sleep); and (4) no use.

We used the Wilcoxon rank-sum test for continuous variables and Fisher’s exact test for categorical variables to compare baseline characteristics in participants with and without polycythemia. We used logistic regression to examine the association between polycythemia and potential risk factors, which were determined a priori based on clinical plausibility. Polycythemia risk factors and potential confounding variables included age, sex, race, BMI, enrollment center, current smoking status, pack-years of cigarette smoking, lung function parameters (FEV₁, % predicted and DLCO % predicted), quantitative chest CT measurements (% emphysema, % air trapping, Pi10), relative PA enlargement (PA/A ratio > 1), resting SpO₂, EID, use of LTOT, and COPD comorbidities. Among all COPDGene clinical centers, Denver, Colorado (5280 feet above sea level) is significantly higher in altitude compared to other clinical centers and therefore enrollment center adjustment was based on participants being enrolled in a Denver versus non-Denver clinical center to control for differences in altitude. Multicollinearity among predictive variables was investigated using the variance inflation factor. We first examined the association between polycythemia and each risk factor, adjusting for the core covariates including age, sex, race, BMI, enrollment center, current smoking status, pack-years of cigarette smoking, and LTOT use. We then conducted a multivariable logistic regression that included all polycythemia risk factors with a suggestive statistical significance (p < 0.1) when adjusting for the core covariates. For all regression analyses we used participants with complete data for the outcome, all predictor variables,
and core covariates. To reduce bias in estimates of coefficients, we used Firth's logistic regression analyses when encountering rare events and/or quasi-separation of data [34, 35].

Self-identified race can serve as a proxy for one's genetic ancestry though may be correlated with socioeconomic status (SES). We performed a sensitivity analysis to investigate the potential contribution of SES to our observed association of polycythemia with self-reported race, by including education level and income with race in the multivariable model. In a separate sensitivity analysis, we excluded participants with anemia (hemoglobin ≤ 13 g/dL in males and ≤ 12 g/dL in females) since anemic participants may have excess comorbidities and unmeasured confounders compared to non-anemic participants [36].

We then conducted another sensitivity analysis, excluding participants enrolled in the Denver clinical center to assess for possible confounding by pathophysiology features enriched in or unique to Denver participants. Due to a decreased number of participants with polycythemia in the analyses excluding Denver participants, we restricted the logistic regression to adjustment for age, sex, race, and variables with statistical significance in the multivariable logistic model for all participants. Given that COPD severity and LTOT use could differ between current and former smokers, as a secondary analysis we examined polycythemia risk factors stratified by smoking status. Given LTOT was mostly prescribed to patients with hypoxemia, we performed a subgroup analysis in participants with resting desaturation (SpO2 ≤ 95%) and/or EID versus normal resting SpO2 (> 95%) without EID.

A two-sided p value < 0.05 was considered statistically significant for all tests. All analyses were conducted using R version 3.6.3 (R Foundation for Statistical Computing, Vienna, Austria).

Results
Sample characteristics
Among 6284 former or current smokers with 10 pack-years or greater of tobacco consumption from the COPDGene study 5-year follow-up, 1928 participants (1054 males and 874 females) with moderate to very severe COPD and available hemoglobin and hematocrit data were included in this study. Of the 1928 participants, 128 (6.6%) individuals including 97 (9.2%) males and 31 (3.5%) females met the 2016 WHO diagnostic criteria for polycythemia. Individuals with polycythemia were more often male, non-Hispanic white, and enrolled in the Denver clinical center compared to individuals without polycythemia (Table 1). Comparing individuals with and without polycythemia, a greater proportion of individuals with polycythemia had severe airflow limitation (GOLD 3); however, a smaller proportion of individuals with polycythemia had very severe airflow limitation (GOLD 4). Participants with GOLD 4 airflow limitation were more often on LTOT (71.2% vs. 39.3%) compared to those with GOLD 3 airflow limitation. In addition, individuals with polycythemia more often had moderate or severe resting hypoxemia and less often reported use of continuous supplemental oxygen compared to individuals without polycythemia.

Risk factors for secondary polycythemia
The association analyses of secondary polycythemia with each risk factor are shown in Table 2. After adjusting for core covariates, FEV1% predicted (odds ratio [OR], 0.98; 95% confidence interval [CI], 0.97–1.00) and DLCO % predicted (OR, 0.98; 95% CI, 0.96–0.99) were inversely associated with risk for polycythemia. Moderate (OR, 1.90; 95% CI, 1.02–3.53) and severe (OR, 3.32; 95% CI, 1.50–7.33) resting hypoxemia were associated with a higher risk for polycythemia. A trend toward association of quantitative CT % emphysema with polycythemia (OR, 1.02; p = 0.051) was found.

The multivariable logistic regression for the association of polycythemia with all suggestive significant predictive variables (p < 0.1 in Table 2) and core covariates is shown in Table 3. In multivariable logistic regression, polycythemia was associated with male sex, non-Hispanic white race (compared to African Americans), current smoking, and enrollment in the Denver clinical center. In addition, severe resting hypoxemia (OR, 3.50; 95% CI, 1.41–8.66) and impaired DLCO (OR, 1.28 for each 10-percent decrease in DLCO % predicted; 95% CI, 1.09–1.49) were associated with increased risk for polycythemia. Use of continuous (OR, 0.13; 95% CI, 0.05–0.35) or nocturnal (OR, 0.46; 95% CI 0.21–0.97) LTOT were associated with decreased risk for polycythemia.

After further adjustment of our multivariable model for education and income, race remained significantly associated with polycythemia with a similar effect size; however, neither education nor income was independently associated with polycythemia (Additional file 1: Table S1). The multivariable logistic regression results did not change significantly after excluding participants with anemia (Additional file 1: Table S2) or after excluding participants enrolled in the Denver clinical center (Additional file 1: Table S3).

Stratified analyses by smoking status
The prevalence of polycythemia in former smokers (n = 1266) was 7.0% in males and 2.5% in females, and in current smokers (n = 662) was 13.6% in males and 5.5% in females. Compared with current smokers, formers smokers were older, more often non-Hispanic white, and more often enrolled in the Denver clinical center (Additional
Furthermore, former smokers appear to have more advanced COPD marked by more severe airflow limitation, lower DLCO % predicted, and more emphysema and air trapping on CT. In addition, compared with current smokers, former smokers more often had moderate or severe resting hypoxemia, and were more often on continuous or nocturnal LTOT.

Among former smokers with severe resting hypoxemia, 9.9% had polycythemia and 37.5% (3/8) of them were not on LTOT; in contrast, 18.5% (5/27) of current smokers with severe resting hypoxemia had polycythemia and 60% (3/5) of them were not on supplemental oxygen (Fig. 1). For individuals with mild resting hypoxemia, 5.4% of former smokers and 10.7% of current smokers had polycythemia; and for individuals with moderate resting hypoxemia, 6.8% of former smokers and 21.3% of current smokers had polycythemia.

Table 1  Baseline characteristics according to the presence of polycythemia

| Characteristic                                      | Polycythemia (N = 128) | No polycythemia (N = 1800) | P value |
|-----------------------------------------------------|------------------------|-----------------------------|---------|
| Age (years)                                         | 66.0 (12.4)            | 67.9 (12.5)                 | 0.17    |
| Sex, male                                           | 97 (75.8)              | 957 (53.2)                  | <0.0001 |
| Race, non-Hispanic white                            | 108 (84.4)             | 1355 (75.3)                 | 0.019   |
| Body mass index (kg/m²)                             | 27.7 (6.9)             | 27.6 (7.9)                  | 0.86    |
| Pack-years of cigarette smoking                     | 48.1 (24.0)            | 46.4 (30.0)                 | 0.24    |
| Enrollment center, Denver                           | 43 (33.6)              | 268 (14.9)                  | <0.0001 |
| Hemoglobin (g/dL)                                   | 16.8 (0.9)             | 13.9 (1.9)                  | <0.0001 |
| Hematocrit (%)                                      | 50.3 (2.5)             | 42.0 (5.2)                  | <0.0001 |
| FEV₁, percent predicted (%)                         | 50.9 (27.5)            | 53.7 (29.0)                 | 0.79    |
| GOLD airflow limitation severity                     |                        |                             |         |
| 2                                                   | 67 (52.3)              | 1033 (57.4)                 |         |
| 3                                                   | 53 (41.4)              | 532 (29.6)                  |         |
| 4                                                   | 8 (6.2)                | 235 (13.1)                  |         |
| DLCO percent predicted (%)                          | 61.2 (30.1)            | 61.7 (30.7)                 | 0.86    |
| Percent emphysema on CT (%)                         | 6.0 (17.2)             | 7.3 (16.8)                  | 0.87    |
| Percent air trapping on CT (%)                      | 33.6 (31.3)            | 35.8 (34.0)                 | 0.39    |
| PI10 on CT (mm)                                     | 2.63 (0.83)            | 2.60 (0.72)                 | 0.86    |
| PA/A ratio, > 1.0                                    | 13 (13.1)              | 285 (20.6)                  | 0.090   |
| Resting SpO₂                                        |                        |                             |         |
| Normal                                              | 50 (39.1)              | 946 (52.6)                  | 0.0042  |
| Mild hypoxemia                                      | 43 (33.6)              | 558 (31.0)                  |         |
| Moderate hypoxemia                                  | 22 (17.2)              | 201 (11.2)                  |         |
| Severe hypoxemia                                    | 13 (10.2)              | 95 (5.3)                    |         |
| Exercise-Induced desaturation                       | 36 (29.3)              | 400 (23.2)                  | 0.12    |
| LTOT use                                            |                        |                             | 0.012   |
| No use                                              | 101 (78.9)             | 1265 (70.3)                 |         |
| Intermittent                                        | 3 (2.3)                | 46 (2.6)                    |         |
| Nocturnal                                           | 16 (12.5)              | 196 (10.9)                  |         |
| Continuous                                          | 8 (6.2)                | 293 (16.3)                  |         |
| Obstructive sleep apnea/CPAP                        | 9 (7.0)/7 (5.5)        | 213 (11.8)/108 (6.0)        | 0.11/0.17|
| Chronic kidney disease                              | 0 (0)                  | 65 (3.6)                    | 0.020   |
| Congestive heart failure                            | 6 (4.7)                | 118 (6.6)                   | 0.57    |
| Diabetes mellitus                                   | 17 (13.3)              | 333 (18.5)                  | 0.15    |

Continuous variables were presented as median (interquartile range); categorical variables were presented as number (percentage).

Bold numbers indicate values with statistical significance P < 0.05

FEV₁, forced expiratory volume in 1 s, GOLD Global Initiative for Chronic Obstructive Lung Disease, DLCO diffusing capacity of lung for carbon monoxide, PI10 square root wall area of a theoretical airway of 10 mm internal perimeter, PA/A ratio ratio of the diameter of the pulmonary artery to the diameter of the aorta, SpO₂ oxyhemoglobin saturation measured by oximetry, LTOT long-term oxygen therapy, CPAP continuous positive airway pressure

* These variables had missing data
Table 2 Logistic regressions of each predictive variable on polycythemia

| Predictive variable | OR   | 95% CI   | P value |
|---------------------|------|----------|---------|
| FEV1 percent predicted | 0.98 | 0.97–1.00 | 0.014   |
| DLCO percent predicted | 0.98 | 0.96–0.99 | <0.0001 |
| Percent emphysema on CT | 1.02 | 1.00–1.04 | 0.051   |
| Percent air trapping on CT | 1.01 | 0.99–1.02 | 0.35    |
| Pa10 on CT | 0.99 | 0.70–1.41 | 0.96    |
| PA/A ratio, > 1.0 | 0.80 | 0.42–1.52 | 0.50    |
| Resting SpO2 | Normal (reference) | 1.00 | Mild hypoxemia | 1.30 | 0.83–2.04 | 0.24 |
| | Moderate hypoxemia | 1.90 | 1.02–3.53 | 0.044   |
| | Severe hypoxemia | 3.32 | 1.50–7.33 | 0.0030  |
| Exercise-induced desaturation | 1.48 | 0.95–2.31 | 0.081   |
| Obstructive sleep apnea | No (reference) | 1.00 | Without CPAP use | 0.25 | 0.06–1.06 | 0.060 |
| | With CPAP use | 0.80 | 0.34–1.87 | 0.61    |
| Congestive heart failure | 1.00 | 0.42–2.40 | 1.00    |
| Chronic kidney disease | 0.08 | 0.00–1.31 | 0.076   |
| Diabetes mellitus | 0.68 | 0.39–1.19 | 0.18    |

The reported OR and P values are from logistic regression models for the association of secondary polycythemia with each predictive variable adjusted for a core set of covariates and confounders including age, sex, race, body mass index, enrollment clinical center, smoking status, pack-years of cigarette smoking, and use of long-term oxygen therapy. Bold numbers indicate values with statistical significance P < 0.05.

OR odds ratio, CI confidence interval, FEV1 forced expiratory volume in 1 s, DLCO diffusing capacity of lung for carbon monoxide, Pa10 square root wall area of a theoretical airway of 10 mm internal perimeter, PA/A ratio ratio of the diameter of the pulmonary artery to the diameter of the aorta, SpO2 oxyhemoglobin saturation measured by oximetry.

Multivariable logistic regression models were examined separately in former smokers and current smokers (Table 4). In former smokers, impaired DLCO (OR, 1.40 for each 10-percent decrease in DLCO % predicted; 95% CI, 1.13–1.72) was associated with increased risk for polycythemia, while using LTOT continuously (OR, 0.24; 95% CI, 0.08–0.71) was associated with decreased risk; there was not a significant association between polycythemia and any severity of resting hypoxemia. In current smokers, moderate resting hypoxemia (OR, 1.10; 95% CI, 0.95–1.26), severe resting hypoxemia (OR, 1.13; 95% CI, 0.98–1.30), and EID (OR, 2.66; 95% CI, 1.38–5.11) were associated with increased risk for polycythemia. Continuous LTOT use (OR, 0.02; 95% CI 0.00–0.39) was associated with decreased risk of polycythemia. DLCO was not significantly associated with polycythemia in current smokers.

Table 3 Multivariable logistic regression for polycythemia in COPD

| Predictive variable | OR   | 95% CI   | P value |
|---------------------|------|----------|---------|
| Sex, male | 3.60 | 2.20–5.90 | <0.0001 |
| Race, non-Hispanic white | 3.33 | 1.71–6.50 | 0.0004 |
| Age at visit (year) | 0.99 | 0.95–1.02 | 0.35    |
| Center, Denver | 4.42 | 2.38–8.21 | <0.0001 |
| Body mass index (kg/m2) | 1.03 | 0.99–1.07 | 0.19    |
| Smoking status, current | 2.55 | 1.49–4.38 | 0.0007  |
| Pack-years of smoking | 0.99 | 0.98–1.00 | 0.20    |
| FEV1% predicted | 1.00 | 0.98–1.01 | 0.59    |
| DLCO % predicted | 0.98 | 0.96–0.99 | 0.0022  |
| Percent emphysema on CT | 0.99 | 0.98–1.01 | 0.31    |
| Resting SpO2 | Normal (reference) | 1.00 | Mild desaturation | 1.02 | 0.60–1.72 | 0.95 |
| | Moderate desaturation | 1.43 | 0.68–2.99 | 0.35    |
| | Severe desaturation | 3.50 | 1.41–8.66 | 0.0068  |
| Exercise-induced desaturation | Continuous | 1.64 | 0.96–2.77 | 0.068  |
| LTOT use | No use (reference) | 1.00 | Intermittent | 0.49 | 0.12–2.04 | 0.32 |
| | Nocturnal | 0.46 | 0.21–0.97 | 0.041   |
| | Continuous | 0.13 | 0.05–0.35 | <0.0001 |
| Obstructive sleep apnea | No diagnosis (reference) | 1.00 | Without CPAP treatment | 0.39 | 0.11–1.41 | 0.15 |
| | With CPAP treatment | 0.91 | 0.36–2.27 | 0.84    |
| | Chronic kidney disease | 0.13 | 0.01–0.24 | 0.16    |

The reported OR and P values are from a single multivariable regression model. Bold numbers indicate values with statistical significance P < 0.05.

OR odds ratio, CI confidence interval, FEV1 forced expiratory volume in 1 s, DLCO diffusing capacity of lung for carbon monoxide, SpO2 oxyhemoglobin saturation measured by oximetry, LTOT long-term oxygen therapy, CPAP continuous positive airway pressure.

Stratified analyses by desaturation status

In subjects with desaturation at rest or exercise, nocturnal (OR, 0.44; 95% CI 0.19–0.99) and continuous LTOT (OR, 0.10; 95% CI 0.03–0.30) were associated with reduced risk for polycythemia (Additional file 1: Table S5). In participants without desaturation, we were not able to detect an association between LTOT use and polycythemia likely due to a very small number of participants (N=2) who had polycythemia were on LTOT (Additional file 1: Table S6).

Discussion

In this cohort of current and former smoking COPD patients from across the US, the overall prevalence of secondary polycythemia was 6.6% and was significantly higher in males, non-Hispanic whites, participants
enrolled in Denver, and current smokers. A lower DLCO % predicted, severe resting hypoxemia, and exercise-induced desaturation (EID) were associated with a higher risk for polycythemia. Use of LTOT was associated with a lower risk for polycythemia.

Although secondary polycythemia has long been identified as a comorbidity in COPD, the prevalence of polycythemia in a contemporary sample of individuals with COPD was not well-established. Cote and colleagues reported a prevalence of polycythemia of 6% in 683 COPD outpatients from a single US clinical center [9]. Two other cohort studies, each less than 300 participants, evaluated the prevalence of polycythemia in European COPD outpatients [12, 13]. Studies based on hospitalized COPD patients or severe COPD patients receiving LTOT may have inaccurate polycythemia prevalence estimates due to selection and misclassification biases [10, 11, 37]. The COPDGene study prospectively enrolled a large number of non-Hispanic white and African American current and former smokers with and without COPD from multiple clinical centers across the US. COPDGene study participants covered a wide distribution of ages and had a balanced sex distribution.

Our study found a significantly higher risk of polycythemia in male COPD subjects compared to female subjects (even when accounting for COPD severity) an observation not well-documented previously. The underlying cause for the sex discrepancy in polycythemia prevalence is unknown. Of note, the cutoff values for hemoglobin and hematocrit in the updated 2016 WHO diagnostic criteria of polycythemia vera are less different by sex (0.5 g/dL difference in hemoglobin and 1% difference in hematocrit) than the former criteria (2 g/dL difference in hemoglobin). That said, even the current diagnostic criteria for polycythemia may not fully account for the baseline hemoglobin/hematocrit differences between males and females and may contribute to the observed sex difference in secondary polycythemia risk. Additionally, we found non-Hispanic whites with COPD were at higher risk for polycythemia compared with African Americans, which may be due to a lower baseline hemoglobin level in African Americans [38, 39]. Race remained significantly associated with polycythemia after adjusting for education and income. However, we are unable to rule out confounders including other more detailed socioeconomic measures and environmental effects. As self-reported race and genetic ancestry are highly correlated in the COPDGene study, it is possible that an ancestry specific effect on red cell traits may account for the association between self-reported race and polycythemia. Also, African Americans in the COPDGene study tended to have less severe COPD which might have further contributed to the observed racial difference in polycythemia risk, even with the adjustment.

Fig. 1  A Proportion of participants with polycythemia, B proportion of participants with polycythemia who were not on long-term oxygen therapy (LTOT) according to severity of resting oxygen desaturation stratified by smoking status.
for COPD severity in multivariable regression models [40].

Study participants enrolled in the Denver clinical center were found to have significantly higher risk for secondary polycythemia compared to those enrolled in clinical centers closer to sea level. Living at high altitude is associated with increased COPD mortality [41, 42], and healthy highlanders are more likely to have polycythemia [43], together suggesting a possible complex interplay between COPD, high altitude, and polycythemia. Denver participants had lower resting SpO2 compared to non-Denver participants after adjustment of COPD severity [44], which likely reflects high-altitude induced hypoxemia. In the present study, resting SpO2 and EID were adjusted for in regression analyses, though may not have sufficiently accounted for differences in the pattern and magnitude of hypoxemia experienced by Denver and non-Denver study participants. It is unclear whether high altitude is a risk factor for polycythemia independent from the effects of hypoxemia. In addition, Denver study participants tended to have more severe COPD, and may have high-altitude related environmental exposures, lung mechanics, and coexisting cardiopulmonary conditions different from non-Denver participants [45]. Those largely unknown factors may have mediated or confounded the association between Denver location and polycythemia despite the adjustment for lung function and quantitative CT measurements in our analyses. Though, in a sensitivity analysis of polycythemia associations excluding Denver participants, the remaining risk factors for polycythemia including male sex, non-Hispanic white race, and severe oxygen desaturation, were similar to the analysis that included Denver participants.

In the present study, severe resting hypoxemia was associated with higher risk for polycythemia whereas continuous or nocturnal use of LTOT were associated

### Table 4: Multivariable logistic regression on polycythemia stratified by smoking status

| Predictive variable | Former smokers (N = 1266) |  | Current smokers (N = 662) |  |
|---------------------|---------------------------|---|---------------------------|---|
|                     | OR  | 95% CI          | P value | OR  | 95% CI          | P value |
| Sex, male           | 4.60 | 2.29–9.25       | <0.0001 | 2.89 | 1.42–5.91       | 0.0036 |
| Race, non-Hispanic white | 2.96 | 1.02–8.59       | 0.046   | 3.60 | 1.56–8.30       | 0.0026 |
| Age at visit (year) | 0.98 | 0.94–1.02       | 0.34    | 0.99 | 0.95–1.04       | 0.81   |
| Center, Denver      | 4.22 | 1.82–9.75       | 0.0008  | 5.59 | 2.16–14.45      | 0.0004 |
| Body mass index (kg/m²) | 1.01 | 0.95–1.07       | 0.80    | 1.05 | 0.99–1.12       | 0.79   |
| Pack-years of smoking | 0.99 | 0.98–1.00       | 0.21    | 1.00 | 0.98–1.01       | 0.71   |
| FEV1% predicted     | 1.00 | 0.98–1.02       | 0.90    | 0.99 | 0.96–1.01       | 0.37   |
| DLCO% predicted     | 0.97 | 0.95–0.99       | 0.0016  | 0.99 | 0.97–1.01       | 0.46   |
| Percent emphysema on CT | 0.97 | 0.94–1.01       | 0.17    | 1.01 | 0.96–1.06       | 0.81   |
| Resting SpO2        |     |                 |         |     |                 |         |
| Normal (reference)  | 1.00 |                 |         | 1.00 |                 |         |
| Mild desaturation   | 0.93 | 0.45–1.91       | 0.84    | 0.98 | 0.47–2.07       | 0.96   |
| Moderate desaturation | 0.75 | 0.27–2.10       | 0.58    | 4.00 | 1.28–12.54      | 0.017  |
| Severe desaturation | 2.10 | 0.64–6.87       | 0.22    | 8.23 | 1.93–35.07      | 0.0044 |
| Exercise-induced desaturation | 1.19 | 0.60–2.39       | 0.62    | 2.66 | 1.18–6.01       | 0.019  |
| LTOT use            |     |                 |         |     |                 |         |
| No use (reference)  | 1.00 |                 |         | 1.00 |                 |         |
| Intermittent        | 0.70 | 0.16–3.11       | 0.64    | 0.28 | 0.01–11.96      | 0.51   |
| Nocturnal           | 0.63 | 0.26–1.53       | 0.31    | 0.47 | 0.12–1.83       | 0.28   |
| Continuous          | 0.24 | 0.08–0.71       | 0.0095  | 0.02 | 0.00–0.39       | 0.011  |
| Obstructive sleep apnea |     |                 |         |     |                 |         |
| No diagnosis (reference) | 1.00 |                 |         | 1.00 |                 |         |
| Without CPAP treatment | 0.15 | 0.01–2.40       | 0.18    | 0.96 | 0.25–3.70       | 0.95   |
| With CPAP treatment | 1.24 | 0.39–3.95       | 0.71    | 0.39 | 0.08–1.82       | 0.23   |
| Chronic kidney disease | 0.20 | 0.01–3.29       | 0.26    | 0.38 | 0.02–6.50       | 0.50   |

The reported OR and P values are from a single multivariable regression model for each smoking status strata

Bold numbers indicate values with statistical significance P < 0.05

OR odds ratio, CI confidence interval, FEV1 forced expiratory volume in 1 s, DLCO diffusing capacity of lung for carbon monoxide, SpO2 oxyhemoglobin saturation measured by oximetry, LTOT long-term oxygen therapy, CPAP continuous positive airway pressure
with lower risk for polycythemia, which indicates a strong association between uncorrected severe hypoxemia and polycythemia in COPD subjects. These findings are consistent with the longstanding understanding of chronic hypoxemia leading to secondary polycythemia in COPD. In a smoking-stratified analysis, former smokers were older and had more advanced COPD and hypoxemia severity compared to current smokers. Moderate resting hypoxemia, severe resting hypoxemia, and exercise-induced desaturation were associated with polycythemia in current smokers but not in former smokers. The proportion of participants with moderate or severe resting hypoxemia receiving LTOT was substantially lower in current smokers compared to former smokers, and continuous LTOT was associated with a decreased risk for polycythemia in both current and former smokers. Taken together, these findings suggest that differences in prescription of LTOT between current and former smokers (most likely due to safety issues in prescribing oxygen to current smokers) may account for the observed increased prevalence of secondary polycythemia in current smokers with COPD. Current smokers have higher and more variable COHb levels compared with non-smokers [46, 47]. \(\text{SpO}_2\) measured by oximetry may overestimate oxyhemoglobin level depending on the amount of COHb in blood [48]. Blood COHb level was not available in this study. As a result, the \(\text{SpO}_2\) measurement in our study may have upward bias in current smokers and result in a systematic less severe categorization of hypoxemia in current smokers.

The present study describes an independent association between impaired DLCO and increased risk for polycythemia, though the underlying mechanism accounting for this association remains unknown. Impaired DLCO can be related to more severe emphysema, concomitant interstitial lung disease, and pulmonary hypertension (PH) in COPD [49, 50]. In the current study, percent emphysema on CT showed a suggestive positive association with polycythemia in single variable regression but not in the multivariable regression which included DLCO. A possible explanation is that DLCO captured emphysema severity and additionally provided information of other underlying mechanisms contributing to polycythemia. Also, as a surrogate of invasively diagnosed PH, relative pulmonary artery (PA) enlargement on CT (PA/A ratio > 1) was not significantly associated with polycythemia in current study, though a direct measurement of pulmonary artery pressure was not available [29, 51]. First, it should be noted that the PA/A ratio measurement occurred approximately 5 years prior to the CBC measurements used to classify individuals as having secondary polycythemia, possibly introducing noise and misclassification bias to the association of PA/A ratio with polycythemia. Another possible explanation of the lack of association of PA/A ratio with polycythemia is that COPD patients with concomitant PH are prone to hospitalizations, which are associated with anemia [52, 53]. Notably, in stratified analysis DLCO was not significantly associated with polycythemia in current smokers. One possible explanation could be the association was mitigated by an increased variability of DLCO measurement in current smokers. COHb is known to affect DLCO measurement through occupation of hemoglobin binding sites and decreasing driving pressure of carbon monoxide transport from alveoli to blood, with a total effect of reducing measured DLCO [54]. In the present study DLCO was not corrected for COHb, which may have biased the estimation of association between DLCO and polycythemia in current smokers to an unknown direction or magnitude. Other possible causes of the null association between DLCO and polycythemia in current smokers include lack of power (same direction of effect estimate in current and former smokers), less severely impaired DLCO in current smokers compared with former smokers (smaller estimate of effect size in current smokers), and heavier cigarette smoking in study participants with less severe COPD.

Secondary polycythemia may have important clinical impact, including various comorbidities (e.g., pulmonary hypertension and venous thromboembolism) and mortality, on COPD patients. This study has important clinical implications related to the interpretation of and intervention on polycythemia in COPD patients. First, the present study clarifies that the prevalence of secondary polycythemia is considerable (~6%) in contemporary US COPD patients, especially in males and current smokers. Second, the presence of polycythemia in COPD patients may warrant an active screening of uncorrected severe hypoxemia, which is a predictor of mortality in COPD [55, 56]. LTOT use in COPD patients with severe resting hypoxemia improves survival and was also found to be associated with lower risk for polycythemia in our study [57–59]. Polycythemia can be easily discovered through a complete blood count, one of the most routinely acquired labs in clinical practice. As a result, a careful evaluation of polycythemia may provide a valuable opportunity to uncover uncorrected hypoxemia in COPD patients. Third, DLCO may be helpful in the evaluation of COPD patients with polycythemia, in whom a low DLCO might prompt an evaluation of concomitant interstitial lung disease or pulmonary vascular disease if hypoxemia alone fails to justify the presence of polycythemia.

The strengths of this study include a large cohort of contemporary COPD patients with extensively curated phenotypes including post-bronchodilator spirometry, DLCO, quantitative chest CT measurements, and LTOT.
use. CBCs were drawn from participants in stable clinical conditions rather than during COPD exacerbations or hospitalizations which would misclassify polycythemia based on acute medical events.

Limitations of this study include the cross-sectional design, which precludes inference of directionality or causality between exposure and outcome variables. Oxygen saturation was measured by pulse oximetry instead of arterial blood gas analysis, which might result in measurement bias [60]. Our available data did not allow us to definitely exclude polycythemia vera, though the prevalence of PV in US is quite low [61, 62]. Finally, LTOT use was self-reported, and information about the setting of initial prescription, follow-up adjustment, or barriers to LTOT use was not available.

Conclusions
In conclusion, in a large sample of current and former smoking individuals with COPD and moderate to very severe airflow limitation, we found a substantial prevalence of polycythemia. The prevalence of polycythemia was significantly higher in males and current smokers. Severe resting hypoxemia, impaired DLCO, and living at high altitude (Denver) were risk factors for polycythemia; whereas, continuous or nocturnal LTOT use were protective against secondary polycythemia in COPD. The longitudinal clinical impact of polycythemia and whether additional risk assessment for polycythemia can lead to improved COPD outcomes and management, such as a more in-depth evaluation for chronic hypoxemia, requires further study.

Abbreviations
6MWT: Six-minute walk test; BMI: Body mass index; CBC: Complete blood count; CI: Confidence interval; COHb: Carboxyhemoglobin; COPD: Chronic obstructive pulmonary disease; COPDGene: Genetic Epidemiology of COPD; CPAP: Continuous positive airway pressure; CT: Computed tomography; DLCO: Diffusing capacity of lung for carbon monoxide; EID: Exercise-induced desaturation; FEV1: Forced expiratory volume in 1 s; FVC: Forced vital capacity; GOLD: Global Initiative for Chronic Obstructive Lung Disease; LTOT: Long-term oxygen therapy; OR: Odds ratio; OSA: Obstructive sleep apnea; PA: Pulmonary artery; PA/A ratio: Pulmonary artery to aorta diameter ratio; PH: Pulmonary hypertension; PI10: Square root wall area of a theoretical airway of 10 mm internal perimeter; PV: Polycythemia vera; SES: Socioeconomic status; SpO2: Oxyhemoglobin saturation; WHO: World Health Organization.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12890-021-01585-5.

Additional file 1. Table S1. Multivariable logistic regression for polycythemia in COPD with further adjustment for education and income. Table S2. Multivariable logistic regression on polycythemia in subjects without anemia. Table S3. Multivariable logistic regression on polycythemia in subjects not enrolled in Denver. Table S4. Baseline characteristics by current smoking status. Table S5. Multivariable logistic regression on polycythemia stratified by desaturation status. Table S6. Distribution of Long-term oxygen therapy uses on polycythemia by desaturation status.

Acknowledgements
We thank the participants and the investigators who have participated in the COPDGene study. Investigator information and full acknowledgements for the COPDGene study are provided in supplemental material (Additional file 2).

Authors' contributions
JZ, EKS, MHC, and BDH contributed substantially to study conception and design, data analysis and interpretation, and manuscript writing and revision. BJM, RCW, DLD, and JMW contributed to data interpretation and manuscript revision. All authors read and approved the final manuscript.

Funding
BDH is supported by NIH K08 HL136928, U01 HL089856, R01 HL147148, and R01 HL135142. MHC is supported by R01 HL135142, R01 HL137927, U01 HL089856, and R01 HL147148. JMW is supported by NIH R01HL148215 and UH3TR002450. DLD is supported by PO1 HL132623 and PO1 HL114501. The project described was supported by Award Numbers U01 HL089897 and Award Number U01 HL089856 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health. COPDGene is also supported by the COPD Foundation through contributions made to an Industry Advisory Board that has included AstraZeneca, Bayer Pharmaceuticals, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Novartis, Pfizer, and Sunovion. The content of the manuscript is the sole responsibility of the authors and the above-mentioned funding bodies had no role in the design of the study; the collection, analysis, and interpretation of data; and in writing the manuscript.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
Institutional review board (IRB) approval was obtained at each of the participating study centers (Additional file 2) prior to study initiation. All participants provided written informed consent.

Consent for publication
Not applicable.

Competing interests
JZ reports no conflict of interest. DLD reports grant support from Bayer and honoraria from Novartis. EKS reports grant support from GlaxoSmithKline and Bayer. BJM reports funding from the NHLBI for the COPDGene study; grants and medical advisory boards from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, and Sunovian; grant from Pearl, consultant for Third Pole, personal fees for DSBM from Spiration and Shire/Baxalta, CME fees from Projects in Knowledge, Wolter Kluwer Health, Eastern Pulmonary Society, National Jewish Health and Novartis; Medical advisory boards from Theravance, Novartis, Phillips, Science 24/7, and Verona. RCW reports no conflict of interest. JMW reports research support from Bayer AG, Mereo BioPharma, and Vertex Pharmaceuticals; and consulting for Mereo BioPharma, GlaxoSmithKline, AstraZeneca, and Boehringer Ingelheim. MHC reports grant funding from GSK and Bayer and consulting and speaking fees from Illumina and AstraZeneca. BDH reports no conflict of interest.

Author details
1 Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, USA. 2 Channing Division of Network Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA. 3 Division of Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital,
Received: 28 December 2020  Accepted: 6 July 2021  Published online: 14 July 2021

References

1. Smith JR, Landaw SA. Smokers’ polycythemia. N Engl J Med. 1978;298(1):6–10.
2. Calverley PM, Leggett RJ, McElderry L, Rennley DC. Cigarette smoking and secondary polycythemia in hypoxia cor pulmonale. Am Rev Respir Dis. 1982;125(3):507–10.
3. Samareh Fekri M, Tabouli M, Azizi Shoul S, Mirzaee M. Prevalence and predictors associated with severe pulmonary hypertension in COPD. Am J Resp Med. 2018;36(2):277–80.
4. Nakamura A, Kasamatsu N, Hashizume I, Shirai T, Hanazona S, Momiki S, et al. Effects of hemoglobin on pulmonary arterial pressure and pulmonary vascular resistance in patients with chronic emphysema. Respiration. 2000;67(5):503–6.
5. Ryan SF. Pulmonary embolism and thrombosis in chronic obstructive emphysema. Am J Pathol. 1963;43:767–73.
6. Nadeem O, Gui J, Ornstein DL. Prevalence of venous thromboembolism in patients with secondary polycythemia. Clin Appl Thromb Hemost. 2013;19(4):363–6.
7. Schwarcz TH, Hogan LA, Endean ED, Roitman IT, Kazmers A, Hyde GL. Relationship between polycythemia and in-hospital mortality in chronic obstructive pulmonary disease and without chronic obstructive pulmonary disease. AJR Am J Roentgenol. 2013;201(3):W460–70.
8. Patel BD, Coxson HO, Pillai SG, Agusti AG, Calverley PM, Donner CF, et al. Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;178(S):500–5.
9. Wells JM, Washko GR, Han MK, Abbas N, Nath H, Mamay AJ, et al. Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med. 2012;367(10):913–21.
10. Iyer AS, Wells JM, Vishin S, Bhatt SP, Wille KM, Dransfield MT. CT scan-measured pulmonary artery to aorta ratio and echocardiography for detecting pulmonary hypertension in severe COPD. Chest. 2014;145(4):824–32.
11. Guo L, Chughtai AR, Jiang H, Gao L, Yang Y, Yang Y, et al. Relationship between polycythemia and in-hospital mortality in chronic obstructive pulmonary disease patients with low-risk pulmonary embolism. J Thorac Dis. 2016;8(11):3119–31.
12. Chambellan A, Chailleux E, Similowski T, Group AO. Predictive value of the hematocrit in patients with severe COPD receiving long-term oxygen therapy. Chest. 2005;128(3):1201–8.
13. Ferrari M, Manea L, Anton K, Bruzzone P, Meneghello M, Zamboni F, et al. Anemia and hemoglobin serum levels are associated with exercise capacity and quality of life in chronic obstructive pulmonary disease. BMC Pulm Med. 2015;15:58.
14. Boutou AK, Karar S, Hopkinson NS, Polkey MJ. Anemia and survival in chronic obstructive pulmonary disease: a dichotomous rather than a continuous predictor. Respiration. 2013;85(5):26–31.
15. Kent BD, Mitchell PD, McNicholas WT. Hypoxemia in patients with COPD: cause, effects, and disease progression. Int J Chron Obstruct Pulmon Dis. 2011;6:199–208.
16. Barbuti T, Thiele J, Gisslinger H, Finazzi G, Vannucchi AM, Toffoli A. The 2016 revision of WHO classification of myeloproliferative neoplasms: clinical and molecular advances. Blood Rev. 2016;30(6):453–9.
17. Sagone AL, Bae B, Balcerzak SP. Smoking as a cause of erythrocytosis. Ann Intern Med. 1997;127(4):512–5.
18. Regan EA, Hokanson JE, Murphy JR, Make B, Lynch DA, Beatty TH, et al. Genetic epidemiology of COPD (COPDGene) study design. COPD. 2010;7(1):32–43.
19. Cho MH, McDonald M-LN, Zhou X, Mattheisen M, Castaldi PJ, Henth CP, et al. Risk loci for chronic obstructive pulmonary disease: a genome-wide association study and meta-analysis. The Lancet Respir Med. 2014;2(3):214–25.
20. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–38.
42. Ezzati M, Horwitz ME, Thomas DS, Friedman AB, Roach R, Clark T, et al. Attitude, life expectancy and mortality from ischaemic heart disease, stroke, COPD and cancers: national population-based analysis of US counties. J Epidemiol Community Health. 2012;66(7):e17.
43. Penaloza D, Arias-Stella J. The heart and pulmonary circulation at high altitudes: healthy highlanders and chronic mountain sickness. Circulation. 2007;115(9):1132–46.
44. Kim DK, Jacobson FL, Washko GR, Casaburi R, Make BJ, Crapo JD, et al. Clinical and radiographic correlates of hypoxemia and oxygen therapy in the COPDGene study. Respir Med. 2011;105(8):1211–21.
45. Stream JO, Luks AM, Grisom CK. Lung disease at high altitude. Expert Rev Respir Med. 2009;3(6):635–50.
46. Turner JA, McNicol MW, Sillett RW. Distribution of carboxyhaemoglobin concentrations in smokers and non-smokers. Thorax. 1986;41(1):25–7.
47. Wald N, Howard S, Smith PG, Bailey A. Use of carboxyhaemoglobin levels to predict the development of diseases associated with cigarette smoking. Thorax. 1975;30(2):133–40.
48. Barker SJ, Tremper KK. The effect of carbon monoxide inhalation on pulse oximetry and transcutaneous PO2. Anesthesiology. 1987;66(5):677–9.
49. Grydeland TB, Thorsen E, Dirksen A, Jensen R, Coxson HO, Pillai SG, et al. Quantitative CT measures of emphysema and airway wall thickness are related to DL(ICO). Respir Med. 2011;105(3):343.
50. Seeger W, Adir Y, Barbera JA, Champion H, Coghlan JG, Cottin V, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol. 2013;62(25 Suppl):D109–16.
51. Ng CS, Wells AU, Padley SP. A CT sign of chronic pulmonary arterial hypertension: the ratio of main pulmonary artery to aortic diameter. J Thorac Imaging. 1999;14(4):270–8.
52. Martinez-Rivera C, Portillo K, Munoz-Fener A, Martinez-Ortiz ML, Molins E, Serra P, et al. Anemia is a mortality predictor in hospitalized patients for COPD exacerbation. COPD. 2012;9(3):241.
53. Almagro P, Cabrera FJ, Diez J, Boixeda R, Alonso Ortiz MB, Munio C, et al. Comorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD: the EPOC en Servicios de medicina interna (ESMI) study. Chest. 2012;142(5):1126–33.
54. Graham BL, Brusasco V, Burgos F, Cooper BG, Jensen R, Kendrick A, et al. 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. Eur Respir J. 2017;49(1):160016.
55. Nizet TA, van den Bishout FJ, Heijdra YF, van de Ven MJ, Mulder PC, Folgering HT. Survival of chronic hypercapnic COPD patients is predicted by smoking habits, comorbidity, and hypoxemia. Chest. 2005;127(6):1904–10.
56. Coleta KD, Silveira LV, Lima DF, Rampinelli EA, Godoy I, Godoy I. Predictors of first-year survival in patients with advanced COPD treated using long-term oxygen therapy. Respir Med. 2008;102(4):512–8.
57. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med. 1980;93(3):391–8.
58. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet. 1981;1(8222):681–6.
59. Cranston JM, Crockett AJ, Moss JR, Alpers JH. Domiciliary oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;4:CD001744.
60. Chan ED, Chan MM, Chan MM. Pulse oximetry: understanding its basic principles facilitates appreciation of its limitations. Respir Med. 2013;107(6):789–99.
61. Ma X, Vanasse G, Cartmel B, Wang Y, Selinger HA. Prevalence of polycythemia vera and essential thrombocythemia. Am J Hematol. 2008;83(5):359–62.
62. Mehta J, Wang H, Iqbal SU, Мesa R. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014;55(3):595–600.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.